Rotavirus outer capsid proteins VP4 and VP7 (VP4/VP7)

Rotavirus outer capsid proteins VP4 and VP7 are the primary antigenic determinants of Rotavirus A, the leading cause of severe diarrhea in children (Source: WHO, 2021). VP7 is a 37-kDa glycoprotein that forms the outer shell, while VP4 is an 87-kDa protease-cleaved protein that forms spikes essential for cell attachment and penetration (Source: UniProt P12473, P12472). These proteins are the targets of neutralizing antibodies, which are the primary correlate of protection against infection (Source: PubMed PMID: 28253456). Vaccines such as Rotarix and RotaTeq utilize these epitopes to prime the immune system, inducing both humoral (IgA) and cellular responses (Source: CDC, 2020). The interaction between these epitopes and the immune system is critical for developing long-term immunity and reducing the global burden of rotavirus-related mortality. Therapeutic challenges include the high genetic diversity of these proteins, necessitating polyvalent vaccine strategies to cover multiple G and P serotypes (Source: NIH, 2023). Safety monitoring is essential due to the historical association of rotavirus vaccines with a small increased risk of intussusception (Source: StatPearls, 2023).

Other names

VP4VP7P proteinG proteinRotavirus neutralization antigensOuter capsid glycoprotein VP7Protease-cleaved spike protein VP4

Vaccines containing or expressing VP4 and VP7 epitopes induce the production of neutralizing antibodies (IgA and IgG) and T-cell responses. These antibodies bind to the viral surface, preventing the virus from attaching to or entering host enterocytes in the small intestine (Source: PubMed PMID: 28253456).